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BACKGROUND. Metabolic syndrome refers to a cluster of conditions that includes
hypertension, dyslipidemia, central adiposity, and high blood glucose levels. Over
the past decade, a growing body of literature suggests that metabolic syndrome
may be associated with several different forms of cancer. Because prostate cancer
risk is highest among African Americans, and these men, similarly, are more
prone to developing specific features of the metabolic syndrome, including
hypertension and type-2 diabetes, any relationships would have a significant
impact on developing strategies for the primary prevention of prostate cancer.
METHODS. The Flint Men’s Health Study is a community-based, case-control
study of prostate cancer conducted exclusively among African Americans. Pros-
tate cancer cases and controls completed an interviewer-administered question-
naire that asked about the respondent’s history of high blood pressure and
diabetes. All men also participated in a physical examination in which several
measures of body composition, including waist circumference, were collected.
RESULTS. Hypertension was reported more commonly among men with prostate
cancer (cases) compared with men in the control group (odds ratio [OR]. 2.4;
95% confidence interval [95% CI], 1.5–3.7), and cases were more likely to have a
waist circumference >102 cm (OR, 1.8; 95% CI, 1.2–2.9). However, self-reported
diabetes was not associated with prostate cancer risk. The men with prostate
cancer also were more likely than controls to exhibit multiple syndrome charac-
teristics (OR, 1.9; 95% CI, 1.2–3.0).
CONCLUSIONS. The current results indicated that features of the metabolic syn-
drome, specifically abdominal obesity and hypertension, are associated with
prostate cancer in African-American men. This relationship, if it is proved causal,
suggests that prevention or control of these conditions eventually may lead to a
reduction in the incidence of prostate cancer in this high-risk minority group.
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I n 1988, Reaven1 described Syndrome X as a cluster of clinical con-ditions that serve as risk factors for cardiovascular disease. Over
the next 2 decades, much has been written about Syndrome X,
which is now commonly called the metabolic syndrome, and its cen-
tral component, insulin resistance. A working definition of the meta-
bolic syndrome was presented in the third report of the National
Cholesterol Education Program Expert Panel on Detection, Evalua-
tion, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III [ATPIII]).2 To be classified with metabolic syn-
drome, individuals must have 3 of the following 5 risk factors: 1)
abdominal obesity (waist circumference >102 cm in men and >88 cm
in women), 2) hypertriglyceridemia (triglycerides 150 mg/dL), 3) low
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high-density lipoprotein (HDL) cholesterol (<40 mg/dL
in men and <50 mg/dL in women), 4) high blood pres-
sure (130/85 mm Hg), and 5) high fasting glucose
(110 mg/dL). A recent report estimated that the meta-
bolic syndrome is highly prevalent in the United States
population and is present in nearly 25% of adults aged
20 years according to the working definition proposed
by the ATPIII.3
It is recognized widely that certain racial and
ethnic groups are predisposed to developing different
features of the metabolic syndrome. Caucasians pres-
ent most often with lipid abnormalities, including
hypertriglyceridemia and low HDL cholesterol3; Afri-
can Americans and Asians present with hypertension;
whereas diabetes is diagnosed more frequently
among Hispanics, Pacific Islanders, and Native Amer-
icans.4 Abdominal obesity has increased drastically
in all men over the past 40 years in the United
States, regardless of race or ethnicity, and nearly 33%
of adult men now have a waist circumference >102
cm (or approximately 40 inches).5
A number of recent reports have suggested that
prostate cancer may be associated with features of
the metabolic syndrome. Using data from a clinical
study of men with prostate cancer in Sweden, Ham-
marsten and Hogstedt6 observed that certain features
of the metabolic syndrome, including both hyperten-
sion and obesity, were more common in men who
had stage T3 cancer compared with men who had
stage T2 cancers. In a prospective study of 16,209
Norwegian men, the presence of the multiple fea-
tures of the metabolic syndrome was associated with
an increased risk of being diagnosed with prostate
cancer over a follow-up of 27 years. Men with meas-
ured values that placed them in the upper quartile
for any 2 features of the metabolic syndrome were
1.23 times more likely to be diagnosed with prostate
cancer (95% confidence interval [95% CI], 1.01–1.50).
Men who exhibited any 3 features were 1.56 times
more likely to be diagnosed prostate cancer com-
pared with the rest of the cohort.7 These data com-
plement a number of studies in the literature that
address the correlations between prostate cancer and
metabolic syndrome,8 body size,9 insulin resistance,10
and hypertension.11
Given the potential association between the fac-
tors that comprise the metabolic syndrome and pros-
tate cancer and the public health importance of
these conditions in African-American men, we set
out to explore the potential correlations between ab-
dominal obesity, hypertension, and diabetes and
prostate cancer using data from the Flint Men’s
Health Study (FMHS), which is a community-based
study of benign and malignant prostate disease in
African-American men between ages 40 years and 79
years who reside in Genesee County, Michigan. The
study represents 1 of the most comprehensive epide-
miological datasets focusing uniquely on African-
American men and the risk for prostate cancer.
MATERIALS AND METHODS
Participants
Data collection for the FMHS began in 1996 and
concluded in 2002. Informed consent was obtained
from study participants, and all protocols were
approved by the Institutional Review Board at the
University of Michigan Medical School. African-
American men between ages 40 years and 79 years
were identified from a probability sample with over
sampling of men in older age groups. From the ini-
tial sample of 819 of eligible men, 730 men (89%)
were willing to participate and completed the
detailed, in-home, epidemiologic interview. Men who
reported a history of prostate cancer or a prior
operation on the prostate gland were considered
ineligible for further study. In total, 379 men com-
pleted all aspects of the protocol, including providing
a blood sample for a serum total prostate-specific
antigen (PSA) measurement and undergoing a com-
prehensive urologic examination. Men who had an
abnormal digital rectal examination and/or elevated
total PSA concentration (4.0 ng/mL) were referred
for prostate biopsy. Twenty men who subsequently
were diagnosed with biopsy-confirmed prostate can-
cer were included in the study as cases, and the
remaining 359 men were included in our control
sample.
Prostate cancer case recruitment from the same
community began in 1999 and was completed in
2002. Cases were identified by using the Genesee
County Community-Wide Hospital Oncology Pro-
gram registry, which includes the 3 hospitals for the
county: Hurley Hospital, Genesys Regional Medical
Center, and McLaren Regional Medical Center. Case
participation in the study required 1) an interviewer-
administered survey questionnaire, which gathered
information identical to that of controls with respect
to prostate cancer risk factors and medical condi-
tions; 2) a review of the hospital and registry records
for information on stage, grade, treatment, and pre-
diagnosis PSA value; 3) anthropometric measure-
ments; and 4) a blood sample. In total, 139 African-
American men ages 40 years to 79 years who were
residents of Genesee County and who had been diag-
nosed with prostate cancer completed all aspects of
the case protocol. This number includes men who
were identified either as a result of the initial recruit-
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ment protocol or who were diagnosed with cancer
between the initial survey and follow-up examination
in 2002.
Metabolic Syndrome Features
The survey instrument that was administered to
cases and controls included questions about socioeco-
nomic status, occupation, health behaviors (including
smoking and alcohol consumption), and family his-
tory of cancer. When appropriate, controls were asked
to consider exposures and conditions prior to the
interview, whereas cases were asked about the same
exposures/conditions up until 1 year prior to diagno-
sis. Self-reported information also was used to assess
prior medical history, including hypertension and di-
abetes. Men were asked a series of 3 questions to
determine history of hypertension: 1) ‘‘Has a doctor
ever told you that you have high blood pressure or
hypertension?’’; 2) ‘‘Do you have high blood pressure
at the present time?’’; and 3) ‘‘Do you have high
blood pressure that is controlled by medication?’’
The last question was asked to avoid potential mis-
classification among men who did not report current
high blood pressure because of antihypertensive
medication use. Hypertension was defined as men
reporting that they currently had high blood pressure
or that they currently were using antihypertensive
medication. Cases and controls also were asked,
‘‘Has a doctor ever told you that you have diabetes
or high blood sugar?’’ For this report, height, weight,
and waist measurements were obtained by trained
health professionals.
Statistical Analysis
Crude associations between participant characteris-
tics (age, smoking status, family history, body mass
index [BMI], waist-to-hip ratio, and sedentary physi-
cal activity) and case-control status were tested by
using a chi-square test for categorical variables and
the Wilcoxon rank-sum test for continuous variables
(Table 1). Because age and smoking history were
associated significantly with case-control status in
this study, both factors were included in subsequent
statistical models. Odds ratios (ORs) and 95% CIs
were produced to quantify correlations between spe-
cific features of the metabolic syndrome (Table 2)
and various combinations of features (Table 3) with
case-control status by using logistic regression mod-
els. All tests and statistics were repeated after the
exclusion of men who had insignificant cancers
(defined as cases with biopsy and specimen Gleason
scores 6, maximum tumor dimension 1 cm, loca-
lized tumor stage, and negative lymph node status)
to evaluate any impact of detection bias.
RESULTS
Data available from 498 African American men were
included in this report, including 139 men with pros-
tate cancer (cases) and 359 disease-free controls.
Despite the strategy of over sampling control men in
the older age groups, the cases were significantly
older than the controls (67.4 years  8.8 years vs
62.1 years  10.1 years, respectively; P < .001) (Table
1). The men with prostate cancer, as expected, were
more likely to report a family history of prostate can-
cer in a first-degree relative (father, brother, or son)
compared with controls, although this difference did
not reach statistical significance (21.6% vs 16.4%,
respectively; P ¼ .18). A greater proportion of con-
trols compared with cases reported ever smoking
TABLE 1
Baseline Characteristics of 498 African-American Men Participating







n = 359 P y
Mean age  SD, y 67.4  8.8 62.1  10.1 <.001
Ever smoked, % 66.7 78.3 .016
Family history of prostate cancer, % 21.6 16.4 .179
Mean BMI  SD, kg/m2 28.5  5.7 27.9  5.9 .228
Sedentary, %{ 19.4 19.3 .990
SD indicates standard deviation; BMI, body mass index.
* These results exclude missing data.
y Associated either with the chi-square statistic or the Wilcoxon test.
{ Participants were considered sedentary if they averaged <5 hours of light activity per day (with 1
hour of vigorous activity equal to 5 hours of light activity).
TABLE 2
Adjusted Odds Ratios and 95% Confidence Intervals Associated With
Prostate Cancer According to Specific Features of the Metabolic
Syndrome Among Participants in the Flint Men’s Health Study
Variable
No. of men (%)
OR [95% CI]*Cases Controls
Abdominal obesity
Waist circumference >102 cm 59 (42.8) 102 (28.5) 1.84 [1.17–2.91]
Waist circumference 102 cm 79 (57.2) 256 (71.5)
High blood pressurey
Yes 85 (61.2) 147 (41.1) 2.36 [1.49–3.73]
No 54 (38.8) 211 (58.9)
Diabetes{
Yes 28 (21.7) 64 (17.8) 0.96 [0.55–1.68]
No 101 (78.3) 295 (82.2)
OR indicates odds ratio; 95% CI, 95% confidence interval.
* Results exclude missing data: ORs were adjusted for age and smoking history.
y Based on self-report of current medical treatment for high blood pressure.
{ Based on self-report of disease.
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cigarettes (78.3% vs 66.7%, respectively; P¼ .016). No
significant differences were detected between pros-
tate cancer cases and controls in BMI or sedentary
behavior.
The data collected allowed us to examine 3 of the
5 key features of the metabolic syndrome in African-
American men. The FMHS protocol did not collect in-
formation about lipid profile abnormalities. After
adjustment for age and smoking history, African-Amer-
ican cases were 1.8 times more likely (95% CI, 1.2–2.9)
to have a waist circumference >102 cm compared with
controls (Table 2). Similarly, men who reported cur-
rently having high blood pressure or taking antihyper-
tensive medications were significantly more likely to
have been diagnosed with prostate cancer (adjusted
OR, 2.4; 95% CI, 1.5–3.7). Nearly 20% of FMHS partici-
pants reported a diagnosis of diabetes; however, no
association between diabetes and prostate cancer was
detected in this study population. The removal of 35
men in the case group who had prostate cancer with
low-risk features did not change the statistical signifi-
cance of any of these results (data not shown).
Very few of our study participants (<10%)
demonstrated all 3 features of the metabolic syn-
drome. Furthermore, we observed no differences in
the likelihood of being diagnosed with prostate cancer
between men who exhibited all 3 features compared
with the other men. However, the presence of any 2
features (ie, abdominal obesity and hypertension, ab-
dominal obesity and diabetes, or diabetes and hyper-
tension) was associated significantly with a diagnosis
of prostate cancer (adjusted OR, 1.8; 95% CI, 1.1–2.8).
Of the 3 possible combinations of factors, abdominal
obesity and hypertension exhibited the strongest asso-
ciation with prostate cancer (adjusted OR, 1.9; 95%
CI, 1.1–3.3) (Fig. 1).
DISCUSSION
African-American men have an approximately 1.6-
fold greater chance of being diagnosed with prostate
cancer compared with white men and a 2.4-fold
greater chance of dying from the disease.12 A signifi-
cant amount of research has been completed over
the last decade focusing on factors that may contri-
bute to the disproportionate incidence and mortality
from prostate cancer in this racial group. We have
demonstrated that both abdominal obesity and
hypertension are associated with an increased likeli-
hood of being diagnosed with prostate cancer in
African-American men. This observation, if it is con-
firmed as a causal relation, has important biologic
and health-policy implications. Given the prevalence
and modifiable nature of these features, control or
prevention of these conditions may represent a
sound strategy for the primary prevention of prostate
cancer as well as cardiovascular disease in this high-
risk minority group.
The link between specific features of the meta-
bolic syndrome and prostate cancer risk focuses pri-
marily on altered serum concentrations of insulin-
like growth factors (IGFs) and associated binding
proteins, sex steroid hormones, and sex-steroid bind-
ing globulin (SHBG).13,14 It has been demonstrated
that insulin resistance and hyperinsulinemia sup-
press the production of IGF binding protein 1
(IGFBP-1) and IGFBP-2 in the liver while increasing
the production of IGF-1.13 It has been reported that
TABLE 3
Risk of Prostate Cancer in African American Men With Multiple
Features of Metabolic Syndrome
Features of metabolic syndrome
No. of men (%)
Adjusted OR
[95% CI]*Cases Controls
Exhibits all 3 features of
metabolic syndrome
9 (7.0) 23 (6.4) 0.74 [0.28–1.91]
Exhibits any 2 of 3 features 50 (39.1) 83 (23.2) 1.76 [1.10–2.83]
OR indicates odds ratio; 95% CI, 95% confidence interval.
* Results exclude missing data: ORs were adjusted for age and smoking history.
FIGURE 1. Combined features of the metabolic syndrome in African-Amer-
ican men with and without prostate cancer. The values are expressed as a
percentage of the total number of either cases or controls. White bars indi-
cate case data, and the hatched bars correspond to data from the control
group. AO indicates abdominal obesity; DM, diabetes mellitus; HBP, high
blood pressure.
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IGF-1 contributes to the initiation and progression of
prostate cancer through a number of mechanisms,
including increased proliferation of both normal and
neoplastic prostate cells and inhibition of apopto-
sis.15–18 Increased insulin production also has been
shown to inhibit the production of SHBG, resulting
in higher concentrations of bioavailable testosterone
and estradiol, which some have proposed also may
promote the development and progression of pros-
tate cancer. However, most current investigations of
the direct relation between circulating testosterone
and prostate cancer risk have not supported this
hypothesis.19,20 It is noteworthy that Hsing et al.
observed a correlation between insulin resistance
and prostate cancer among Chinese men that was
independent of serum IGF, SHBG, and sex steroid
hormone concentrations; this correlation suggests
that there may be alternative mechanisms in prostate
carcinogenesis, such as inflammation and oxidative
stress, and further investigation is warranted.10,21–23
Our observations largely are consistent with pre-
vious studies in predominately Caucasian populations.
However, not all investigations have consistently
observed an association between features of the meta-
bolic syndrome and prostate cancer risk. A recent
study that used data gathered from the third National
Health and Nutrition Examination Survey reported an
increased prevalence of metabolic syndrome, as de-
fined by the ATPIII, among all cancer survivors versus
individuals without any history of cancer (258 per
1000 population vs 184 per 1000 population, respec-
tively). However, metabolic syndrome was character-
ized less frequently among individuals who had a
history of prostate cancer than among individuals
without a history of prostate cancer.24
Of the three features of the metabolic syndrome
that were measured in FMHS participants, hyperten-
sion was associated most strongly with prostate can-
cer risk. It has been shown that hypertension is
associated with overall cancer mortality, but data
supporting an association between high blood pres-
sure and prostate cancer incidence are scant. Fried-
man25 studied >58,000 men who were followed in
the Kaiser Permanente Medical Care Program
between 1964 and 1994 and identified 2297 men
with prostate cancer that resulted in 464 deaths. No
statistically significant association was observed
between high blood pressure or resting heart rate
and the subsequent diagnosis of prostate cancer.
Fitzpatrick et al.11 analyzed hypertension, heart rate,
antihypertensive medication use, and the subsequent
diagnosis of prostate cancer in a cohort of 2442 men
from an observational study of adults aged 65
years. Although no association was detected in their
study between high blood pressure and incident
prostate cancer over 5.6 years of follow-up, the use
of antihypertensive medications protected against
the diagnosis of prostate cancer. In our study, we
elected to use current reports of antihypertensive
medication use in our definition of hypertension. It
is worth noting that 11% of cases and 15% of con-
trols in our study reported that they did not have
high blood pressure because they were receiving
medication for this condition. We do not have full
medication histories and, thus, are unable to tease
out potential associations with regard to specific
classes of antihypertensive medications. Future re-
search is needed in this area to explore more fully
the potential associations between blood pressure
elevation, use of antihypertensive medications, and
prostate cancer diagnosis. Abdominal obesity was
associated with prostate cancer among study partici-
pants. Although we observed that men with a larger
waist circumference (>102 cm) were more likely to
be diagnosed with prostate cancer, no correlation
was observed between BMI and prostate cancer. This
discrepancy in findings may highlight an important
limitation in the use of BMI as a measure of obesity,
in that it does not make any distinction between
muscle and fat mass. BMI as a surrogate measure for
obesity is particularly problematic among older indi-
viduals, because lean body mass generally is replaced
by fat mass with increasing age. Waist circumference
is considered a superior measure of the metabolic
consequences of obesity and often is used in addi-
tion to BMI in epidemiologic investigations of an-
thropometric risk factors for disease.26–28
There are additional limitations in the current
FMHS report that should be considered when inter-
preting these results. First, as mentioned above, se-
rum analysis of HDL cholesterol and triglycerides
was not performed among participants in the study;
thus, evaluation for this investigation was limited to
3 of the 5 documented features of the metabolic syn-
drome: abdominal adiposity, hypertension, and dia-
betes. The guidelines set forth by the ATPIII require
the presence of 3 criteria for a diagnosis of meta-
bolic syndrome. Within those guidelines, coupled
with the relatively low proportion of participants that
exhibited all 3 indicators measured in the study, we
were unable to properly determine the prevalence of
metabolic syndrome in the study population. How-
ever, the 3 features that were evaluated independ-
ently in this study are highly prevalent in African
Americans, so that prevention or control of these
individual features potentially may have an impact
on the incidence of prostate cancer in this popula-
tion.
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We acknowledge the presence of bias in this
study that limits our ability to infer a causal relation
between these features and prostate cancer risk.
Because of the retrospective study design and the in-
dolent progression of prostate cancer in most cases,
we cannot establish firmly a temporal sequence
between the onset of the conditions of interest and
prostate cancer among the cases. In addition, reli-
ance on self-reported information about the diag-
noses of diabetes and hypertension introduces the
potential for misclassification bias. However, prior
studies indicated reasonable consistency and reliabil-
ity in the reporting of these comorbidities, particu-
larly among those reporting medication use to treat
the condition.29,30 Also, as mentioned above, there is
the possibility of detection bias, in that prostate can-
cer may be more likely to be diagnosed among men
who pursue regular medical care for the treatment of
hypertension and/or diabetes. Recent findings pub-
lished by Fowke et al suggest that the correlation
observed in some studies between obesity and inci-
dent prostate cancer may be explained in part by
increased frequency of physician examination and
PSA testing associated with obesity-related condi-
tions.31 FMHS study controls were asked to report
whether or not they had ever had a PSA test prior
to their recruitment and testing as part of the study
protocol. However, we did not detect a difference
in the proportion of controls who reported prior
prostate cancer screening between men who had a
waist circumference >102 cm compared with men
who had smaller waists (49% vs 43%, respectively;
P ¼ .32).
In conclusion, the current results suggest that
hypertension and abdominal obesity are associated
with prostate cancer among African-American men.
The epidemic increase in the prevalence of obesity
in the United States over the past few decades,
coupled with the racial disparity in the incidence,
treatment, and/or control of associated comorbid-
ities, such as hypertension and diabetes, between
African-American men and white men indicates that
further study will be necessary to confirm these find-
ings and should be considered a significant public
health priority. The potential benefit would be
observed not only by a reduction in the direct ad-
verse health consequences of these conditions but
also indirectly by potentially influencing the risk of
prostate cancer in these men.
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